Christopher Raymond
Stock Analyst at Piper Sandler
(2.62)
# 2,056
Out of 4,784 analysts
134
Total ratings
51.82%
Success rate
-0.54%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $0.66 | +1,273.84% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $71.44 | +76.37% | 15 | Feb 20, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $138 → $135 | $138.37 | -2.44% | 20 | Feb 18, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $1.71 | +133.92% | 3 | Feb 11, 2025 | |
| ARDX Ardelyx | Maintains: Neutral | $7 → $8 | $4.93 | +62.27% | 7 | Jan 27, 2025 | |
| BPMC Blueprint Medicines | Maintains: Neutral | $109 → $119 | $88.72 | +34.13% | 4 | Jan 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $533 | $492.69 | +8.18% | 8 | Jan 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,195 → $1,013 | $637.36 | +58.94% | 7 | Jan 27, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $135 → $140 | $37.82 | +270.17% | 5 | Jan 13, 2025 | |
| INZY Inozyme Pharma | Maintains: Overweight | $43 → $30 | $0.92 | +3,160.16% | 1 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $40.33 | +78.53% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $220 | $205.29 | +7.17% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $1.59 | +717.61% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $4.16 | +1,702.88% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $27.65 | +174.86% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $1.16 | +762.07% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $9.77 | +237.77% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $1.93 | +262.69% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $6.43 | +553.19% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $6.48 | +239.51% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.91 | +109.42% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $25 | $7.33 | +241.06% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $306.95 | -6.17% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $30.28 | +35.40% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $44.15 | -36.58% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $73.05 | -45.24% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $4.32 | +1,983.33% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.73 | +5,449.13% | 2 | Mar 13, 2020 |
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $0.66
Upside: +1,273.84%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $71.44
Upside: +76.37%
Biogen
Feb 18, 2025
Reiterates: Neutral
Price Target: $138 → $135
Current: $138.37
Upside: -2.44%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $1.71
Upside: +133.92%
Ardelyx
Jan 27, 2025
Maintains: Neutral
Price Target: $7 → $8
Current: $4.93
Upside: +62.27%
Blueprint Medicines
Jan 27, 2025
Maintains: Neutral
Price Target: $109 → $119
Current: $88.72
Upside: +34.13%
Vertex Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $492.69
Upside: +8.18%
Regeneron Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $637.36
Upside: +58.94%
Ultragenyx Pharmaceutical
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $37.82
Upside: +270.17%
Inozyme Pharma
Jan 13, 2025
Maintains: Overweight
Price Target: $43 → $30
Current: $0.92
Upside: +3,160.16%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $40.33
Upside: +78.53%
Dec 17, 2024
Maintains: Overweight
Price Target: $212 → $220
Current: $205.29
Upside: +7.17%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $1.59
Upside: +717.61%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $4.16
Upside: +1,702.88%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $27.65
Upside: +174.86%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $1.16
Upside: +762.07%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $9.77
Upside: +237.77%
Jul 1, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $1.93
Upside: +262.69%
Apr 29, 2024
Initiates: Overweight
Price Target: $42
Current: $6.43
Upside: +553.19%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $6.48
Upside: +239.51%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.91
Upside: +109.42%
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $7.33
Upside: +241.06%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $306.95
Upside: -6.17%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $30.28
Upside: +35.40%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $44.15
Upside: -36.58%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $73.05
Upside: -45.24%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $4.32
Upside: +1,983.33%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.73
Upside: +5,449.13%